Severe Eosinophilic Gastroenteritis in a Crohn’s Disease Patient Treated With Infliximab and Adalimumab

Case Report: Hypereosinophilic Syndrome Response to Infliximab in a Patient with Ulcerative Colitis

“…Hematopoietic cell transplantation should be considered as the last therapeutic alternative when everything else has failed [1][2][3][4][5][6][7][8][9][10]. Anti-TNF administration has been reported to induce severe eosinophilic gastroenteritis in a patient with Crohn's Disease [11]. However, we believe, according to our experience that infliximab administration is safe in such patients, and that eosinophilic gastroentritis is more probably to be secondary to the disease instead of the medication.…”

Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment

“…Peripheral eosinophilia is commonly observed despite not being mandatory for diagnosis. In addition, some reports have documented anecdotal cases of eosinophilic gastroenteritis induced by anti-tumor necrosis factor in IBD patients[36,37]. Amongst first-line therapeutic options are a short trial of elemental diet (with the goal of eliminating food antigen exposure) and systemic corticosteroids[31].…”

Eosinophilic Gastroenteritis in an Ulcerative Colitis Patient During Treatment with Tumor Necrosis Factor-alpha Antagonist

“…Interestingly, Muir et al reported a patient with Crohn's disease that developed severe EGE after treatment with infliximab or adalimumab ( 10 ). EGE occurred three months after induction of golimumab in our case.…”

“…If the development of EGE is actually an adverse reaction to the TNF-alpha antagonist, golimumab should be changed to another agent to avoid future flares. However, a previous case report of Crohn's disease reported that switching between TNF-alpha antagonists was not effective ( 10 ). Therefore, it might be desirable to switch to tofacitinib, a Janus kinase (JAK) inhibitor.…”